Biosite has adopted a strategy that encompasses the diagnostic continuum from protein validation to point-of-care diagnostics. Through combined expertise in diagnostic discovery and commercialization they are able to select large market opportunities, access potential markers of disease, identify proteins with high diagnostic utility, apply validated disease markers to advanced testing platforms, bring products to market, and educate physicians and other clinicians on new approaches to diagnosis, thereby benefiting patients.

Their expertise in rapid, high-capacity antibody development, enables high throughput screening of potential diagnostic markers and cost-efficient development of high affinity antibodies for use in commercialized products